Amiodarone-induced thyrotoxicosis: Should surgery be considered?
Ann Endocrinol (Paris)
; 85(2): 136-141, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38246417
ABSTRACT
Amiodarone is the most widely prescribed antiarrhythmic drug worldwide, but induces thyrotoxicosis or hypothyroidism in 15 to 20% of patients. Hyperthyroidism is less frequent than hypothyroidism, and two types of thyrotoxicosis are distinguished according to presence of underlying thyroid disease. Diagnosis is made in case of low TSH and high levels of T3 and T4. Initial treatment is based on anti-thyroid drugs and/or glucocorticoids. Some patients do not respond to medication, which increases the time spent with hyperthyroidism. A long interval between diagnosis and euthyroidism and low left ventricular ejection fraction (LVEF) are predictive of major adverse cardiovascular events. Here, after describing the current state of knowledge of amiodarone-induced thyrotoxicosis, we analyze the literature on the impact of surgery. We suggest that early surgery should be the first option in case of ineffective medical treatment or LVEF<40%. In expert centers, surgical morbidity is no longer different than in other indications for thyroidectomy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tirotoxicosis
/
Amiodarona
/
Hipertiroidismo
/
Hipotiroidismo
Límite:
Humans
Idioma:
En
Revista:
Ann Endocrinol (Paris)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia